Therapy (HBV)

Scientists Explore Two-year Lamivudine Therapy for Hepatitis B

Published in Hepatitis Weekly, September 11th, 2000

Lamivudine is a proven treatment for some patients with hepatitis B virus (HBV). However, the effects of taking this therapy longer than a year have not been thoroughly explored, according to researchers.

Medical investigators in Taiwan have examined the effects of treating HBV patients with lamivudine for two years. Published results of their efforts were made available recently in the journal Gastroenterology.

A research team led by Y.F. Liaw randomized 334 patients to receive either daily lamivudine therapy or a placebo after having already receiving lamivudine for one year. Liaw et al. quantified serum markers for viral progression,...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2000-09-11)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry